|
Indicator |
Total |
Male |
Female |
% Male |
% Female |
|
HIV infection cases |
6,522 |
4,573 |
1,949 |
70% |
30% |
|
AIDS cases |
2,915 |
2,170 |
745 |
74% |
26% |
|
Deaths |
1,455 |
1,160 |
295 |
80% |
20% |
|
Children (0–14 years) |
|
|
|
|
|
|
HIV infection cases |
90 |
|
|
|
|
|
AIDS cases |
47 |
|
|
|
|
|
Deaths |
12 |
|
|
|
|
As of the end of the reporting period:
|
Indicator |
Number |
|
People living with HIV (PLHIV) |
5,067 (estimated 7,300) |
|
Receiving antiretroviral therapy (ART) |
4,192 citizens |
|
Stage |
Percentage |
|
Diagnosed |
76% |
|
Receiving ART |
80% |
|
Virally suppressed |
86% |
|
Indicator |
Total |
Male |
Female |
% Male |
% Female |
|
HIV infection cases |
364 |
268 |
96 |
74% |
26% |
|
AIDS cases |
130 |
97 |
33 |
75% |
25% |
|
Deaths |
81 |
58 |
23 |
72% |
28% |
|
Children (0–14 years) |
2 |
— |
— |
— |
— |
|
Transmission Route |
% of Total Cases |
|
Heterosexual contact |
81.6% |
|
Homosexual contact |
13% |
|
Injecting drug use |
4.4% |
|
Mother-to-child |
0.5% |
|
Unknown |
0.5% |
|
Month |
New HIV Cases |
AIDS Cases |
Deaths |
|
January |
39 |
8 |
8 |
|
February |
46 |
13 |
3 |
|
March |
44 |
23 |
7 |
|
April |
45 |
26 |
9 |
|
May |
35 |
22 |
6 |
|
June |
44 |
15 |
3 |
|
July |
38 |
6 |
35 |
|
August |
42 |
10 |
8 |
|
September |
31 |
7 |
2 |
|
Total |
364 |
130 |
81 |
|
Age Group |
Jan |
Feb |
Mar |
Apr |
May |
Jun |
Jul |
Aug |
Sep |
Total |
|
0–14 years |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
|
15–24 years |
2 |
1 |
1 |
4 |
1 |
4 |
2 |
0 |
1 |
16 |
|
25–39 years |
13 |
13 |
14 |
11 |
19 |
15 |
12 |
19 |
15 |
131 |
|
40–49 years |
15 |
14 |
19 |
13 |
5 |
15 |
13 |
12 |
9 |
115 |
|
≥50 years |
9 |
16 |
10 |
17 |
10 |
10 |
11 |
11 |
6 |
100 |
|
Unknown |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Total |
39 |
46 |
44 |
45 |
35 |
44 |
38 |
42 |
31 |
364 |
|
Transmission Route |
Jan |
Feb |
Mar |
Apr |
May |
Jun |
Jul |
Aug |
Sep |
Total |
|
Heterosexual |
29 |
40 |
34 |
42 |
33 |
35 |
31 |
34 |
19 |
297 |
|
Injecting drug use |
2 |
1 |
6 |
1 |
0 |
2 |
2 |
1 |
1 |
16 |
|
Homosexual |
8 |
3 |
4 |
2 |
2 |
7 |
5 |
6 |
10 |
47 |
|
Mother-to-child |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
|
Blood transfusion |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Unknown |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
|
Total |
39 |
46 |
44 |
45 |
35 |
44 |
38 |
42 |
31 |
364 |
Per 100,000 population
|
Region |
Rate (per 100,000) |
|
Shirak |
301 |
|
Lori |
274 |
|
Gegharkunik |
250 |
|
Key Population |
Estimated Size |
HIV Prevalence |
|
People who inject drugs (PWID) |
14,110 |
2.6% |
|
Men who have sex with men (MSM) |
22,716 |
5% |
|
Female sex workers (FSW) |
8,140 |
0.2% |
|
Transgender persons (TG) |
1,015 |
2.5% |
|
Intervention |
Number of Beneficiaries |
|
Prevention of mother-to-child transmission (PMTCT) |
29 |
|
Pre-exposure prophylaxis (PrEP) |
97 |
|
Post-exposure prophylaxis (PEP) |
116 |
|
Indicator |
Number |
|
Patients enrolled in treatment |
479 |
|
Patients treated in penitentiary institutions |
56 |
|
Indicator |
Total |
Male |
Female |
% Male |
% Female |
|
HIV infection cases |
480 |
362 |
118 |
75% |
25% |
|
AIDS cases |
121 |
86 |
35 |
71% |
29% |
|
New HIV cases in 2025 |
36 |
— |
— |
— |
— |
|
Receiving ART (as of Sep 30, 2025) |
117 |
— |
— |
— |
— |